106PDEGFR MUTATION DETECTION IN PLASMA OF LUNG TUMOR PATIENTS IN THE ABSENCE OF CONTRIBUTIVE TISSUE IS A RELEVANT ALTERNATIVE FOR PRESCRIPTION OF TYROSINE KINASE INHIBITORS IN A ROUTINE CLINICAL SETTING